Skip to content Skip to menu

Clinical trial expert wins top pharma award

Tuesday, 14 October 2008

Media Release

The 2008 Pat Clear Award has been won by Mitch Kirkman, manager of clinical research at Novartis Pharmaceuticals Australia.

The Award was presented to Mr Kirkman at Medicines Australia’s Annual General Meeting today.

The Pat Clear Award is the innovative pharmaceutical industry’s most prestigious and coveted award. It is presented annually to recognise an outstanding level of commitment by an individual, group or team for the benefit of the Australian pharmaceutical industry.

Mr Kirkman won the Award for his outstanding work as founding chair of Medicines Australia’s Research and Development Taskforce, spearheading the pharmaceutical industry’s efforts to achieve nationally standardised regulation of clinical research in Australia.

Medicines Australia chief executive Ian Chalmers congratulated Mr Kirkman, and said the Award was richly deserved.

“This Award recognises a very significant contribution to our industry,” Mr Chalmers said.

“Mitch has a long and distinguished record of dedicated service to the innovative pharmaceutical industry. He is a very worthy winner of this prestigious Award.

“Under his stewardship, the R&D Taskforce has argued energetically and persuasively for rationalisation of Australia’s fragmented regulatory system for clinical research.

“Clinical trials account for the vast majority of research and development expenditure by Australian pharmaceutical companies. Under Mitch’s chairmanship, the R&D Taskforce has helped secure a much improved regulatory environment for clinical research.

“This means medical research can be conducted more efficiently. Future Australian patients will have earlier access to effective new therapies, unknowingly benefiting from the important work of a classic quiet achiever.”

The Pat Clear Award was established in 2002 to commemorate the contribution Mr Clear made to the pharmaceutical industry in Australia.


Contact Person:

Jamie Nicholson
Media Communications Manager
Phone: 0419 220 293


As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at